Live Breaking News & Updates on Anniversary Annual
Stay updated with breaking news from Anniversary annual. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
March 31, 2022 | The Traffic Club of New York's 116th Anniversary Annual Dinner | The Sheraton Times Square, NY ajot.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajot.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today a. ....
Our six dermatology products are marketed by our partner company, Journey Medical Corporation (“Journey”). Our products generated net revenues of $44.5 million for full-year 2020, compared to full-year 2019 net revenues of $34.9 million, representing growth of 28%. Our products generated $13.7 million in revenues in the fourth quarter of 2020, compared to $11.1 million in the fourth quarter of 2019, representing growth of 23%. While we generated revenue growth year-over-year in 2020, sales of our products were impacted by the COVID-19 pandemic, which caused a temporary supply shortage and impacted the ability of our sales force to make in person calls, due to states slowly re-opening. We in-licensed and recently launched our sixth prescription dermatology product. ....
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Bicycle Therapeutics plc: Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Toxin Conjugates (BTCs) and tumor targeted immune cell agonists (TICAs) Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones First clinical trial site outside of the United States opened in ongoing Phase I/II trial of BT8009 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle) technology, today reported financial results for the fourth quarter and full year ended December 31, 2020 and discussed recent corporate updates. ....